

Setting the **Global**  
**Standard for Quality**  
in Laboratory Testing



**P:** +1.610.688.0100  
**Toll Free (US):** 877.447.1888  
**F:** +1.610.688.0700  
**E:** customerservice@clsi.org

950 West Valley Road  
Suite 2500  
Wayne, PA 19087 USA



**CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®**

6 May 2016

To: Recipients of VET01S, 3rd ed.

From: Jennifer K. Adams, MT(ASCP), MSHA

Subject: Editorial Errors of Omission in Tables 1, 2C, 2D, 2G, 2H, and 2J in CLSI Document VET01S

This notification is to inform you of errors of omission in Table 1, Table 2C, Table 2D, Table 2G, Table 2H, and Table 2J in CLSI document VET01S, 3rd ed., *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*.

In Tables 2C, 2G, 2H, and 2J, the unit of measure “U/k” was corrected to “U/kg.” The remaining edits are listed by table, below.

**Table 1:** Enrofloxacin was omitted from the table listing the source of some commercially available antimicrobial disks.

The corrected entry is highlighted in the excerpted row from the **NOTE 5** table, below:

Antimicrobial Agent(s)	Pharmaceutical Industry Sponsor	Location	Contact Information
<b>Enrofloxacin</b> <b>Pradofloxacin</b>	<b>Bayer HealthCare LLC</b>	<b>Shawnee Mission, Kansas, USA</b>	<b>+1-800.422.9874</b>



**Table 2D:** The omitted minimal inhibitory concentration (MIC) breakpoint updates for tetracycline against *Streptococcus pneumoniae* in humans were updated in Table 2D. The added updates, with previously published breakpoints, are highlighted in the excerpt from Table 2D, below.

**Table 2D. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Streptococcus* spp.**

Test/ Report Group	Body Site	Antimicrobial Agent	Organism	Disk Content	Zone Diameter Interpretive Criteria (nearest whole mm)			MIC Interpretive Criteria (µg/mL)			Comments
					S	I	R	S	I	R	
<b>Tetracyclines</b>											
<b>Humans</b>											
		<b>Tetracycline</b>	<i>Streptococcus</i> spp., other than <i>S.</i> <i>pneumoniae</i>	30 µg	≥23	19–22	≤21	≤2	4	≥8	(31) Tetracycline tested as the class representative for susceptibility to chlortetracycline, doxycycline, minocycline, and oxytetracycline. Organisms that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline or minocycline or both.
			<b>S.</b> <b><i>pneumoniae</i></b>		≥28	25–27	≤24	≤1	2	≥4	



**Table 2H:** The omitted minimal inhibitory concentration (MIC) breakpoints for the  $\beta$ -lactam/ $\beta$ -lactam inhibitor combination amoxicillin-clavulanic acid against *Pasteurella multocida* in cats were added to Table 2H. The added rows, with previously published breakpoints, are highlighted in the excerpt from Table 2H, below:

**Table 2H. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Pasteurella multocida***

Test/ Report Group	Body Site	Antimicrobial Agent	Disk Content	Zone Diameter Interpretive Criteria (nearest whole mm)			MIC Interpretive Criteria ( $\mu\text{g/mL}$ )			Comments
				S	I	R	S	I	R	
<b>Aminoglycosides/Aminocyclitols</b>										
<b><math>\beta</math>-Lactam/<math>\beta</math>-Lactam Inhibitor Combinations</b>										
<b>Cats</b>										
A	Skin, soft tissue, UTI	Amoxicillin- clavulanic acid	—	—	—	—	$\leq$ 0.25/ 0.12	0.5/ 0.25	$\geq$ 1/0.5	(1) Amoxicillin-clavulanate breakpoints were determined from an examination of MIC distribution of isolates, efficacy data, and PK-PD analysis of amoxicillin in cats at a dosage of 12.5 mg/kg (amoxicillin) administered every 12 hours orally.

Setting the **Global**  
**Standard for Quality**  
 in Laboratory Testing

P: +1.610.688.0100  
**Toll Free (US):** 877.447.1888  
 F: +1.610.688.0700  
 E: [customerservice@clsi.org](mailto:customerservice@clsi.org)

950 West Valley Road  
 Suite 2500  
 Wayne, PA 19087 USA



**CLINICAL AND  
 LABORATORY  
 STANDARDS  
 INSTITUTE®**

**Table 2J:** The omitted MIC breakpoints for tetracycline against *Histophilus somni* in cattle were added to Table 2J. The added rows, with previously published breakpoints, are highlighted in the excerpt from Table 2J, below:

**Table 2J. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Histophilus somni***

Test/ Report Group	Body Site	Antimicrobial Agent	Disk Content	Zone Diameter Interpretive Criteria (nearest whole mm)			MIC Interpretive Criteria (µg/mL)			Comments
				S	I	R	S	I	R	
<b>Tetracyclines</b>										
<b>Cattle</b>										
A	Respiratory	Tetracycline	—	—	—	—	≤2	4	≥8	(3) Breakpoints derived from PK data of oxytetracycline at 20 mg/kg IM, once, and PD data.  (4) These interpretive criteria are applicable only for the injectable formulations. Tetracycline is the class representative.

If you require any additional clarification regarding this correction, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI, and regret any inconvenience.